Description

Resiquimod (CAS No. 144875-48-9) is a high-purity synthetic imidazoquinoline compound with the molecular formula C₁₇H₂₂N₄O₂. This small molecule immunostimulant is chemically designated as 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol and is provided as a white to off-white crystalline powder. Resiquimod is a potent Toll-like receptor (TLR) 7 and TLR8 agonist known for its ability to induce cytokine production, particularly interferon-alpha, making it valuable for immunological research. Our product is rigorously tested by HPLC and NMR to ensure >98% purity, with batch-specific certificates of analysis available. Suitable for in vitro and in vivo studies, this compound is provided in amber vials under inert atmosphere to ensure stability. Store at -20°C protected from light and moisture.

Properties

• CAS Number: 144875-48-9
• Complexity: 406
• IUPAC Name: 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol
• InChI: InChI=1S/C17H22N4O2/c1-4-23-9-13-20-14-15(21(13)10-17(2,3)22)11-7-5-6-8-12(11)19-16(14)18/h5-8,22H,4,9-10H2,1-3H3,(H2,18,19)
• InChI Key: BXNMTOQRYBFHNZ-UHFFFAOYSA-N
• Exact Mass: 314.17427596
• Molecular Formula: C17H22N4O2
• Molecular Weight: 314.4
• SMILES: CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N
• Topological: 86.2
• Monoisotopic Mass: 314.17427596
• Synonyms: Resiquimod, 144875-48-9, 1-(4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol, Resiquimod [INN], R 848, 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol, UNII-V3DMU7PVXF, V3DMU7PVXF, S 28463, CHEBI:36706, RESIQUIMOD [MI], RESIQUIMOD [USAN], RESIQUIMOD [MART.], CD11301, RESIQUIMOD [WHO-DD], CD-11301, 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-, DTXSID7040603, RESIQUIMOD (MART.), 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol, 1H-Imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-, 4-Amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol, resiquimodum, 1-(4-amino-2-(ethoxymethyl)-1H-imidazo(4,5-c)quinolin-1-yl)-2-methylpropan-2-ol, 1H-Imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-I+-,I+–dimethyl-, 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-I+-,I+–dimethyl-, 4-Amino-2-(ethoxymethyl)-I+-,I+–dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol, 4-Amino-2-(ethoxymethyl)-I+-,I+–dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol, DTXCID5020603, R-848, R848, S-28463, MFCD00937759, Resiquimod (GMP), 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol, CHEMBL383322, R848;S28463, alpha-dimethyl-1H-imidazo(4,5-c)quinoline-1-ethanol, 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol., R848 compound, VML-600, ResiquimodR848?, RX8, R848; Resiquimod, SCHEMBL34159, MLS006010212, GTPL5051, Resiquimod, >=98% (HPLC), 4-Amino-2-(ethoxymethyl)-alpha, BXNMTOQRYBFHNZ-UHFFFAOYSA-N, GLXC-06608, HMS3740O09, HMS5086I07, BCP09103, EX-A1879, BDBM50241029, HY-13740G, NSC828390, s8133, AKOS016003509, CCG-267635, CS-1706, DB06530, NSC-828390, SB17111, 1-(4-Amino-2-ethoxymethyl-imidazo[4,5-c]quinolin-1-yl)-2-methyl-propan-2-ol, s28463, NCGC00370784-01, NCGC00370784-05, AC-35716, AS-30885, FR170507, HY-13740, SMR002530531, SY107476, CS-0645881, NS00071828, R0197, Q426054, SR-01000944954, SR-01000944954-1, BRD-K76210423-001-01-6, BRD-K76210423-001-02-4, 1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methyl-propan-2-ol, 1H-Imidazo[4,5-c]quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-|A,|A-dimethyl-, 4-amino-alpha,alpha-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-ethanol, 4-Amino-alpha,alpha-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol

Application

Resiquimod is widely used as a research tool for studying innate immune responses through its action as a dual TLR7/TLR8 agonist. The compound has shown utility in preclinical studies of antiviral therapies, cancer immunotherapy, and vaccine adjuvants. Researchers employ Resiquimod to investigate cytokine induction pathways, particularly interferon-mediated antiviral defenses. Its ability to stimulate dendritic cell maturation makes it valuable for immunological studies. Recent applications include exploration of topical formulations for dermatological conditions.

If you are interested or have any questions, please contact us at support@atomfair.com

Disclaimer: Sold exclusively for laboratory research. Prohibited for commercial use, diagnostics, or human/animal applications. Buyers assume all compliance liability.